the therapeutic results suggest that the present combination regimen may be indicated for induction treatment of multiple myeloma patients in an advanced stage of the disease , and for treatment of myeloma patients refractory or resistant to melphalan and/or cyclophosphamide .
C0026764
myeloma
C0010583
cyclophosphamide